2026 report · Fiscal years 2023–2025
Big Pharma
Inventory Trends
How 28 of the world’s largest pharmaceutical companies managed inventory—and why the industry’s reported stock reached approximately $170bn in fiscal 2025.
Get the 2026 benchmarkmajor pharmaceutical companies
large-pharma median DIO · FY2023–FY2025
reported FY2025 inventory
regular-pharma median DIO · FY2023–FY2025
Inside the report
One industry. Two sharply different inventory directions.
The public numbers show where inventory is moving. nVentic’s analysis separates structural effects from the signals leaders should investigate further.
- See why median DIO rose 25 days for the higher-revenue cohort while falling 24 days for the lower-revenue cohort.
- Understand how GLP-1 launches, acquisitions and planning choices shaped the sharpest inventory movements.
- Compare reported inventory and DIO across 28 companies over fiscal years 2023 to 2025.
- Connect public benchmark signals to the working-capital opportunity inside your own inventory.
Get the complete report
Register once. Access the full benchmark immediately.
Share your professional details to unlock the official PDF, including all seven exhibits, the methodology and the path from public benchmark to working-capital action.
- Format
- PDF · 3.8 MB
- Edition
- August 2026
- Coverage
- FY2023–FY2025
Move from industry signal to company action
How much working capital is trapped in your inventory?
nVentic connects the benchmark to item-level demand, supply and stock evidence—showing what can be released without putting service at risk.
Discuss your inventory opportunity info@nventic.com